文献速递肝病

瘦型非酒精性脂肪性肝病个体肝病更严重且临床结局更差(NASH-CO研究)

Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study).
PubMed 文献 · Hepatology · 2023-02-24

基于法国Constances队列137,206名受试者的社区研究显示,瘦型受试者NAFLD患病率为5.3%,NAFLD患者中16.3%为瘦型;瘦型NAFLD患者晚期纤维化患病率显著高于非瘦型(3.7% vs 1.7%),且校正后瘦型状态与晚期纤维化、肝脏相关事件、慢性肾病及全因死亡风险升高相关。

要点

  • 瘦型受试者NAFLD患病率为5.3%(95% CI: 5.2-5.4),NAFLD患者中16.3%(95% CI: 15.7-16.8)为瘦型。
  • 瘦型NAFLD患者晚期纤维化患病率显著高于非瘦型(3.7% vs 1.7%,p < 0.01)。
  • 瘦型状态与肝脏相关事件(校正HR=5.84)、慢性肾病(校正HR=2.49)及全因死亡(校正HR=3.01)风险升高相关。

核心结论

  • 该大型社区队列研究证实,瘦型受试者的NAFLD在纤维化、肝病进展、慢性肾病及全因死亡方面更为严重。

研究设计与样本

  • 研究纳入法国全国性Constances队列169,303名参与者,排除过量饮酒、病毒性肝炎或其他肝病后分析137,206名受试者。
  • NAFLD及纤维化诊断采用脂肪肝指数(Fatty Liver Index)和Forns指数。
  • 中位随访时间为3.58年。

主要发现

  • 瘦型受试者NAFLD患病率为5.3%(95% CI: 5.2-5.4),非瘦型NAFLD患者中瘦型占16.3%(95% CI: 15.7-16.8)。
  • 尽管瘦型NAFLD患者代谢特征更优,其晚期纤维化患病率仍显著高于非瘦型(3.7% vs 1.7%,p < 0.01)。
  • 在NAFLD受试者中,校正人口学、代谢危险因素及生活方式后,瘦型状态与晚期纤维化相关(OR=1.26,95% CI: 1.20-1.65,p = 0.005)。
  • 瘦型状态与肝脏相关事件风险升高相关(校正HR=5.84,95% CI: 4.03-8.46)。
  • 瘦型状态与慢性肾病风险升高相关(校正HR=2.49,95% CI: 1.49-4.16)。

关键数值与推荐

  • 瘦型受试者NAFLD患病率为5.3%(95% CI: 5.2-5.4),非瘦型NAFLD患者中瘦型占16.3%(95% CI: 15.7-16.8)。
  • 瘦型NAFLD患者晚期纤维化患病率为3.7%,非瘦型为1.7%(p < 0.01)。
  • 瘦型状态与晚期纤维化的OR=1.26(95% CI: 1.20-1.65,p = 0.005)。
  • 瘦型状态与肝脏相关事件的校正HR=5.84(95% CI: 4.03-8.46)。
  • 瘦型状态与慢性肾病的校正HR=2.49(95% CI: 1.49-4.16),与全因死亡的校正HR=3.01(95% CI: 2.21-4.11)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The severity of liver injury and clinical outcomes in lean individuals with NAFLD is a subject of debate and very few studies have been performed in the general population. The aim of this study was to compare subject characteristics and mortality between lean and nonlean NAFLD in a community setting. APPROACH AND RESULTS: The study population included 169,303 participants from the nationwide Constances cohort. Subjects with excessive alcohol consumption, viral hepatitis, or other liver diseases were excluded and 137,206 subjects were analyzed. The diagnosis of NAFLD and fibrosis was performed using the Fatty Liver Index and the Forns Index. The median follow-up was 3.58 years. The prevalence of NAFLD was 5.3% (95% CI: 5.2-5.4) in lean subjects, while 16.3% (95% CI: 15.7-16.8) of NAFLD subjects were lean. Despite their better metabolic profile, the prevalence of advanced fibrosis was significantly higher in lean than in nonlean NAFLD (3.7% vs. 1.7%, respectively, p < 0.01). Among NAFLD subjects and after adjustment for demographics, metabolic risk factors and lifestyle, lean status was associated with advanced fibrosis (OR=1.26, 95% CI: 1.20-1.65, p = 0.005), an increased risk of liver-related events (adjusted HR=5.84, 95% CI: 4.03-8.46), chronic kidney disease (adjusted HR=2.49, 95% CI: 1.49-4.16), and overall mortality (adjusted HR=3.01, 95% CI: 2.21-4.11). Liver-related events and overall mortality were related to the severity of fibrosis, both in lean and nonlean NAFLD subjects, whatever the usual risk factors. CONCLUSION: This study in a large community-based cohort confirms that NAFLD in lean subjects is more severe for fibrosis, the progression of liver disease, chronic kidney disease, and overall mortality.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Nabi O, Lapidus N, Boursier J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology. 2023. PMID: 36815354. doi:10.1097/HEP.0000000000000329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。